1. Home
  2. CXAI vs MBAI Comparison

CXAI vs MBAI Comparison

Compare CXAI & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

HOLD

Current Price

$0.26

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.66

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CXAI
MBAI
Founded
N/A
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
10.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CXAI
MBAI
Price
$0.26
$1.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.0M
48.1K
Earning Date
04-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$70.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$1.31
52 Week High
$1.49
$3.92

Technical Indicators

Market Signals
Indicator
CXAI
MBAI
Relative Strength Index (RSI) 56.23 47.62
Support Level $0.24 $1.38
Resistance Level $0.38 $1.89
Average True Range (ATR) 0.04 0.15
MACD 0.01 -0.01
Stochastic Oscillator 62.38 24.05

Price Performance

Historical Comparison
CXAI
MBAI

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: